Network Meta-Analysis of MASH Pharmacotherapy Efficacy and Tolerability Rankings

34 studies from 33 publications compare drug efficacy for metabolic dysfunction-associated steatohepatitis. A frequentist network meta-analysis ranks therapies like FGF21 analogs and SGLT2 inhibitors for fibrosis improvement and MASH resolution. The dataset, uploaded by Mengshi Tang in June 2026, compiles results from a systematic review registered as CRD420261292638.

Use Cases

• Ranking drug efficacy for fibrosis improvement based on relative risk values from the network meta-analysis.
• Comparing tolerability profiles of different pharmacological mechanisms using the cluster analysis results.
• Validating the performance of SGLT2 inhibitors against FDA-approved therapies using the reported risk ratios.
• Designing future Phase III trials by identifying therapies with promising preliminary evidence, as highlighted in the conclusions.

Strengths

• Includes data from 34 Phase II/III randomized controlled trials, providing a substantial evidence base.
• Reports specific risk ratios with 95% confidence intervals, such as RR 2.22 for FGF21 analogs and RR 2.27 for SGLT2 inhibitors.
• Employs a two-dimensional cluster analysis to evaluate the balance between efficacy and tolerability.
• Conducted sensitivity analyses that confirmed the robustness of the primary rankings.

Limitations

• The dataset is very small at 11.6 KB, indicating limited scope and likely summary-level data only.
• Row count and column-level documentation are absent; field semantics must be inferred after download.
• The description notes that findings for SGLT2 inhibitors are based on limited histological data from a single pivotal trial.

Provenance

Source

Systematic review of PubMed, Embase, Web of Science, Scopus, and Cochrane Library.

Collection Method

Frequentist network meta-analysis of Phase II/III RCTs involving adults with biopsy-proven MASH.

Freshness

Last updated 2026-06-04 04:30:33; freshness should be verified.